AF
AMRX icon

Allworth Financial’s Amneal Pharmaceuticals AMRX Stock Holding History

Allworth Financial’s Portfolio AMRX Stock Details AMRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$20.9K Sell
1,206
-64
-5% -$877 ﹤0.01% 3161
2026
Q1 		$15.8K Buy
1,270
+195
+18% +$2.62K ﹤0.01% 3163
2025
Q4 		$13.5K Buy
1,075
+149
+16% +$1.71K ﹤0.01% 3054
2025
Q3 		$9.27K Buy
926
+156
+20% +$1.4K ﹤0.01% 3181
2025
Q2 		$6.23K Buy
770
+234
+44% +$1.76K ﹤0.01% 3144
2025
Q1 		$3.98K Hold
536
– – ﹤0.01% 2882
2024
Q4 		$4.57K Sell
536
-73
-12% -$612 ﹤0.01% 2807
2024
Q3 		$5.07K Hold
609
– – ﹤0.01% 2559
2024
Q2 		$4.41K Hold
609
– – ﹤0.01% 2579
2024
Q1 		$3.69K Hold
609
– – ﹤0.01% 2541
2023
Q4 		$3.7K Buy
609
+479
+368% +$2.13K ﹤0.01% 2397
2023
Q3 		$549 Buy
+130
New +$485 ﹤0.01% 3021
2022
Q4 		– Sell
-6,365
Closed -$13K – 3003
2022
Q3 		$13K Buy
+6,365
New +$17.8K ﹤0.01% 1468

Other funds holding AMRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return

Allworth Financial's AMRX Position: Q2 2026 in Review

Allworth Financial reduced its Amneal Pharmaceuticals (AMRX) stake by 5% in Q2 2026, selling an estimated $877 and leaving 1,206 shares worth $20.9K. The position accounts for ﹤0.01% of the portfolio, ranked #3161.

Allworth Financial first reported a position in AMRX in Q3 2022 and has held it in 13 quarters since. 306 funds tracked by Wall St. Rank hold AMRX as of Q2 2026.

  • Allworth Financial held 1,206 shares of Amneal Pharmaceuticals worth $20.9K as of Q2 2026.
  • Allworth Financial sold 64 Amneal Pharmaceuticals shares in Q2 2026, an estimated $877.
  • Amneal Pharmaceuticals made up ﹤0.01% of Allworth Financial's portfolio in Q2 2026, its #3161 holding.
  • Allworth Financial first reported a position in Amneal Pharmaceuticals in Q3 2022 and has held it in 13 quarters since.
  • 306 funds tracked by Wall St. Rank held Amneal Pharmaceuticals as of Q2 2026.

Based on Allworth Financial's 13F filing for Q2 2026, filed 11 Aug 2026.